Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
News
 
The Success of the Initiation of Marketing of FMD® (Hemoporfin)   2013-12-16 14:04

--The Report on Ninth Annual Meeting of Chinese Dermatologist Association
14th – 17th, Nor. 2013
Guangzhou, CHINA

        Annual Meeting of China Dermatologist Association is one of the most important meetings on dermatology in China. The meeting was holding on 14th – 17th, Nor. 2013, in Guangzhou Baiyun International Conference Centre, Guangzhou City, China. Photodynamic technology was highlighted in the meeting and the reports on the theoretical studies and clinical applications of photodynamic technology on dermatology were made by the experts all over China.

        The announcement of the marketing of FMD®, as a class 1.1 new drugs and a brand new chemical entity globally, independently developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. was performed in the noon of 15th, Nor. 2013. FMD® is the third generation of the photosensitive reagent and officially comes to market in 2014. FMD® is indicated on the treatment of port wine stain. The meeting of the announcement was backed by FDZJ. More than 500 experts on dermatology and the directors of Dermatology Departments of more than 20 key hospitals in China took part in the meeting.

        Professor Zhu Xuejun, the former chairman of the association, Professor Wang Baoxi, the present chairman of the association, and Professor Gu Ying, who initiated the R & D of hemoporfin, played the parts of chairmen. Professor Du Ping of the First Hospital of Peking University, who was the team leader to conduct the clinical trial phase III of hemoporfin made a presentation, “Evidence-based Medical Research of Photodynamic Therapy with Hemoporfin to Treat Port Wine Stain”.

        At the meeting, Mr. Wang Haibo, the chairman of FDZJ made a passionate speech to report the hard process of R & D of FMD® and describe the bright future of the clinical application of FMD®. The experts of 8 hospitals in charge of the clinical trial phase III and the team leaders all took part in the meeting and witnessed the historical moment of the marking of FMD® (Fig. 1). All the guests were looking forward to the marking of the new photosensitive reagent and hope the product use in clinics to benefit the patients suffering from port wine stain.

        The photodynamic therapy is rapidly developed and widely popularized in China. More than 600 hospitals have been practicing the therapy. Photodynamic therapy is used in the treatment of dermatological std and tumor, and in the cosmetology in China. We expect the marketing of more photosensitive reagents to serve the clinical needs and more academic progress on this field.

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2019-0143    沪ICP备10027510号-1